Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.

Human Blood Substitutes, Once Dead, Now Resuscitated

Human Blood Substitutes, Once Dead, Now Resuscitated

A nanotechnology derived artificial red blood cell could be used in life-saving situations like trauma accidents or the battlefield where donated blood is unavailable.

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.